Retention of Bioresearch Investigators a Major Issue for FDA, GAO Report Says

The recruitment and retention of Bioresearch Monitoring (BIMO) program investigators has been a thorn in the side of the FDA that’s negatively impacted trial inspections, a Government Accountability Office (GAO) audit has found.
Source: Drug Industry Daily